| 101 |
16119973 | A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data. | 2005 |
1 |
| 102 |
16180941 | Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. | 2005 |
1 |
| 103 |
16249351 | Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. | 2005 Oct |
1 |
| 104 |
16415488 | The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. | 2005 |
2 |
| 105 |
16689132 | [Nonsteroidal antirheumatics and the kidney]. | 2005 |
2 |
| 106 |
17532719 | Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects. | 2005 |
1 |
| 107 |
14713756 | Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. | 2004 Feb |
1 |
| 108 |
14756580 | Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis. | 2004 |
1 |
| 109 |
14760808 | Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. | 2004 Feb |
1 |
| 110 |
14965322 | Clinical pharmacology of novel selective COX-2 inhibitors. | 2004 |
1 |
| 111 |
14977803 | Effect of rofecoxib on platelet aggregation and blood loss in gynaecological and breast surgery compared with diclofenac. | 2004 Apr |
1 |
| 112 |
15050982 | Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea. | 2004 Apr |
2 |
| 113 |
15082814 | Applying a research ethics committee approach to a medical practice controversy: the case of the selective COX-2 inhibitor rofecoxib. | 2004 Apr |
3 |
| 114 |
15086362 | Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. | 2004 Apr |
1 |
| 115 |
15117884 | Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. | 2004 May |
1 |
| 116 |
15133778 | Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. | 2004 May |
1 |
| 117 |
15136366 | Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. | 2004 May |
2 |
| 118 |
15145696 | Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1). | 2004 Jun 15 |
2 |
| 119 |
15151910 | Cognitive decline with chronic meningitis secondary to a COX-2 inhibitor. | 2004 Jul |
1 |
| 120 |
15179440 | Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib). | 2004 Dec |
3 |
| 121 |
15182793 | Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy. | 2004 May |
1 |
| 122 |
15194006 | Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. | 2004 Jul 15 |
1 |
| 123 |
15200656 | Rofecoxib administration to paediatric patients undergoing adenotonsillectomy. | 2004 Jul |
1 |
| 124 |
15232052 | Delirium From the COX-2 inhibitor refecoxib. | 2004 Jul-Aug |
1 |
| 125 |
15329003 | Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. | 2004 Jun |
1 |
| 126 |
15355480 | Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients. | 2004 Oct |
1 |
| 127 |
15462687 | The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. | 2004 Oct |
1 |
| 128 |
15486258 | Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. | 2004 Oct 15 |
1 |
| 129 |
15494133 | Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. | 2004 Nov 15 |
2 |
| 130 |
15521372 | Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. | 2004 Oct |
1 |
| 131 |
15534440 | Tocolysis and preterm labour. | 2004 Dec |
1 |
| 132 |
15548128 | Market withdrawal of Vioxx: is it time to rethink the use of COX-2 inhibitors? | 2004 Nov-Dec |
1 |
| 133 |
15561649 | Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada. | 2004 Sep |
1 |
| 134 |
15570733 | The Vioxx withdrawal: latest in the COX-2 controversies. | 2004 Nov |
1 |
| 135 |
15570734 | A world without Vioxx: to COX-2 or not to COX-2? | 2004 Nov |
2 |
| 136 |
15576013 | COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. | 2004 Oct 29 |
1 |
| 137 |
15607056 | [Analysis of cost-minimization treatment with paracetamol or COX-2 inhibitors (rofecoxib) for pain from arthrosis of the knee or hip]. | 2004 Dec |
1 |
| 138 |
15623076 | [Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?]. | 2004 Oct |
2 |
| 139 |
15623263 | COX-2 inhibitor use after Vioxx: careful balance or end of the rope? | 2004 Nov |
1 |
| 140 |
15648986 | A randomized crossover trial of tenoxicam compared with rofecoxib for postoperative dental pain control. | 2004 Dec |
1 |
| 141 |
15865061 | Docking studies on NSAID/COX-2 isozyme complexes using contact statistics analysis. | 2004 Nov |
3 |
| 142 |
16146090 | Effect of nimesulide-a preferential COX-2 inhibitor on arterial blood pressure, compared to ketoprofen. | 2004 |
1 |
| 143 |
17516707 | Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). | 2004 |
1 |
| 144 |
12445672 | Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. | 2003 Jan 10 |
1 |
| 145 |
12490541 | Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor. | 2003 Feb |
1 |
| 146 |
12522725 | [Development of opioid tolerance -- molecular mechanisms and clinical consequences]. | 2003 Jan |
1 |
| 147 |
12557133 | Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. | 2003 Feb |
1 |
| 148 |
12583353 | Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxib. | 2003 Feb |
1 |
| 149 |
12604692 | Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation. | 2003 Mar |
1 |
| 150 |
12629931 | Cyclooxygenase-2: from arthritis treatment to new indications for the prevention and treatment of cancer. | 2003 Jan-Feb |
2 |